Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma: Final appraisal document

DRAFT guidance recommends this regimen, within marketing authorisation, as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant, only if company provides it according to commercial arrangement.

National Institute for Health and Care Excellence